We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why the Market Dipped But Adma Biologics (ADMA) Gained Today
Read MoreHide Full Article
In the latest trading session, Adma Biologics (ADMA - Free Report) closed at $15.15, marking a +1.03% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.61%. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 0.93%.
The stock of infectious disease drug developer has fallen by 3.85% in the past month, leading the Medical sector's loss of 4.48% and undershooting the S&P 500's loss of 2.25%.
Market participants will be closely following the financial results of Adma Biologics in its upcoming release.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.96 per share and a revenue of $639.74 million, indicating changes of +60% and +25.4%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 12.35% higher within the past month. Adma Biologics is currently a Zacks Rank #2 (Buy).
Investors should also note Adma Biologics's current valuation metrics, including its Forward P/E ratio of 15.7. Its industry sports an average Forward P/E of 18.89, so one might conclude that Adma Biologics is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 142, finds itself in the bottom 43% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why the Market Dipped But Adma Biologics (ADMA) Gained Today
In the latest trading session, Adma Biologics (ADMA - Free Report) closed at $15.15, marking a +1.03% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.61%. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 0.93%.
The stock of infectious disease drug developer has fallen by 3.85% in the past month, leading the Medical sector's loss of 4.48% and undershooting the S&P 500's loss of 2.25%.
Market participants will be closely following the financial results of Adma Biologics in its upcoming release.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.96 per share and a revenue of $639.74 million, indicating changes of +60% and +25.4%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 12.35% higher within the past month. Adma Biologics is currently a Zacks Rank #2 (Buy).
Investors should also note Adma Biologics's current valuation metrics, including its Forward P/E ratio of 15.7. Its industry sports an average Forward P/E of 18.89, so one might conclude that Adma Biologics is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 142, finds itself in the bottom 43% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.